128 related articles for article (PubMed ID: 7769275)
21. Impairment of T cell receptor-dependent stimulation in CD4+ lymphocytes after contact with membrane-bound HIV-1 envelope glycoprotein.
Schwartz O; Alizon M; Heard JM; Danos O
Virology; 1994 Jan; 198(1):360-5. PubMed ID: 7903129
[TBL] [Abstract][Full Text] [Related]
22. Patterns of antibody reactivity to selected human immunodeficiency virus type 1 (HIV-1) gp160 epitopes infected individuals grouped according to CD4+ cell levels.
Warren RQ; Wolf H; Zajac RA; Boswell RN; Kanda P; Kennedy RC
J Clin Immunol; 1991 Jan; 11(1):13-21. PubMed ID: 1708780
[TBL] [Abstract][Full Text] [Related]
23. Specific western blot bands are associated with initial CD4+ lymphocyte counts in human immunodeficiency virus seroconverters. The Navy HIV Working Group.
Garland FC; Garland CF; Gorham ED; Brodine SK; Weiss PJ
Ann Epidemiol; 1994 Jan; 4(1):27-31. PubMed ID: 7911377
[TBL] [Abstract][Full Text] [Related]
24. Production of transmembrane and secreted forms of tumor necrosis factor (TNF)-alpha by HIV-1-specific CD4+ cytolytic T lymphocyte clones. Evidence for a TNF-alpha-independent cytolytic mechanism.
Liu AY; Miskovsky EP; Stanhope PE; Siliciano RF
J Immunol; 1992 Jun; 148(12):3789-98. PubMed ID: 1351088
[TBL] [Abstract][Full Text] [Related]
25. N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity.
Sjölander S; Bolmstedt A; Akerblom L; Horal P; Olofsson S; Morein B; Sjölander A
Virology; 1996 Jan; 215(2):124-33. PubMed ID: 8560759
[TBL] [Abstract][Full Text] [Related]
26. Peptides containing multideterminant clusters of human immunodeficiency virus envelope induce murine and human T-cell responses in diverse histocompatibility types.
Berzofsky JA; Pendleton CD; Clerici M; Ahlers J; Lucey DR; Putney SD; Shearer GM
Trans Assoc Am Physicians; 1991; 104():69-77. PubMed ID: 1845157
[No Abstract] [Full Text] [Related]
27. Characterization of serum antibody responses to recombinant HIV-1 gp160 vaccine by enzyme immunoassay. NIAID AIDS Vaccine Clinical Trials Network.
Viscidi R; Ellerbeck E; Garrison L; Midthun K; Clements ML; Clayman B; Fernie B; Smith G
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1251-6. PubMed ID: 1706607
[TBL] [Abstract][Full Text] [Related]
28. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
Cooney EL; McElrath MJ; Corey L; Hu SL; Collier AC; Arditti D; Hoffman M; Coombs RW; Smith GE; Greenberg PD
Proc Natl Acad Sci U S A; 1993 Mar; 90(5):1882-6. PubMed ID: 8446603
[TBL] [Abstract][Full Text] [Related]
29. Induction of antibodies to the envelope protein of the human immunodeficiency virus by immunization with monoclonal anti-idiotypes.
Zaghouani H; Goldstein D; Shah H; Anderson S; Lacroix M; Dionne G; Kennedy R; Bona C
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5645-9. PubMed ID: 2062842
[TBL] [Abstract][Full Text] [Related]
30. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
31. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
Srivastava IK; VanDorsten K; Vojtech L; Barnett SW; Stamatatos L
J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968
[TBL] [Abstract][Full Text] [Related]
32. Computer predictions of antigenic domains in human immunodeficiency virus-1 envelope glycoprotein: comparison with reported experimental data.
Becker Y
Virus Genes; 1990 Apr; 3(4):323-41. PubMed ID: 1693457
[TBL] [Abstract][Full Text] [Related]
33. Quantitative analysis of human immunodeficiency virus type 1 antibody reactivity by western immunoblots: evaluation of relative antibody levels in seropositive individuals and mothers.
Geffin RB; Lai SH; Hutto C; Scott GB; Scott WA; Master M; Parks WP
J Infect Dis; 1992 Jan; 165(1):111-8. PubMed ID: 1727880
[TBL] [Abstract][Full Text] [Related]
34. Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the human immunodeficiency virus type 1 envelope glycoprotein: definition of minimum epitopes and analysis of the effects of sequence variation.
Johnson RP; Trocha A; Buchanan TM; Walker BD
J Exp Med; 1992 Apr; 175(4):961-71. PubMed ID: 1372650
[TBL] [Abstract][Full Text] [Related]
35. Humoral immune responses in human HIV-1 infection clearance of initial burst of virus replication and protection against disease progression.
Goudsmit J
Int Rev Immunol; 1992; 8(1):65-81. PubMed ID: 1374113
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 env DNA vaccine administered to rhesus monkeys elicits MHC class II-restricted CD4+ T helper cells that secrete IFN-gamma and TNF-alpha.
Lekutis C; Shiver JW; Liu MA; Letvin NL
J Immunol; 1997 May; 158(9):4471-7. PubMed ID: 9127013
[TBL] [Abstract][Full Text] [Related]
37. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein.
Gao F; Weaver EA; Lu Z; Li Y; Liao HX; Ma B; Alam SM; Scearce RM; Sutherland LL; Yu JS; Decker JM; Shaw GM; Montefiori DC; Korber BT; Hahn BH; Haynes BF
J Virol; 2005 Jan; 79(2):1154-63. PubMed ID: 15613343
[TBL] [Abstract][Full Text] [Related]
38. Propagation of CD4+ T cells specific for HIV type 1 envelope gp120 from chronically HIV type 1-infected subjects.
Cohen S; Tuen M; Hioe CE
AIDS Res Hum Retroviruses; 2003 Sep; 19(9):793-806. PubMed ID: 14585210
[TBL] [Abstract][Full Text] [Related]
39. Human CD4+ cytolytic T lymphocyte responses to a human immunodeficiency virus type 1 gp160 subunit vaccine.
Stanhope PE; Clements ML; Siliciano RF
J Infect Dis; 1993 Jul; 168(1):92-100. PubMed ID: 8099941
[TBL] [Abstract][Full Text] [Related]
40. Anchor sequence-dependent endogenous processing of human immunodeficiency virus 1 envelope glycoprotein gp160 for CD4+ T cell recognition.
Polydefkis M; Koenig S; Flexner C; Obah E; Gebo K; Chakrabarti S; Earl PL; Moss B; Siliciano RF
J Exp Med; 1990 Mar; 171(3):875-87. PubMed ID: 1968506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
